Business
ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update
LYON, France, May 12, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2026 and provides a business update.
About this update from Adocia Sa
LYON, France, May 12, 2026--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the first quarter of 2026 and provides a business update. "As the market for metabolic peptides evolves toward peptide combinations, BioChaperone® is establishing itself as the leading technology for stabilizing these new formulations. The positive results of the feasibility studies conducted, as well as the recent launch of a new study, have led us to prioritize the development of this technology," declares Olivier Soula, CEO and cofounder of Adocia. "Thanks to the ongoing support of Vester Finance, our largest shareholder alongside the Soula family, our cash runway is secured until the beginning of the second quarter of 2027. To ensure the acceleration and success of our flagship BioChaperone® technology, we are reallocating our human and financial resources and slowing down the development of AdoShell®," added Mathieu-William Gilbert, CFO-COO of Adocia. First Quarter 2026 financial results Financial highlights for the quarter include the following: Detail of the revenue The Q1 2025 revenue of €0.6 million was related to the feasibility study on the AdOral® technology applied to a novel incretin conducted for an undisclosed partner. Net Cash Position The Company's cash position stood at €12.0 million as of March 31, 2026, compared to €17.2 million as of December 31, 2025. The cash burn related to Q1 2026 activities amounted to €5.1 million, compared to €6.6 million for Q1 2025 (excluding financing). Net financial debt (excluding IFRS 16 impacts), consisting exclusively of state-guaranteed loans (PGE), amounted to €1.3 million as of March 31, 2026, down €0.7 million compared to December 31, 2025, following the repayments made during the quarter. The maturity of these loans remains at end August 2026. The cash position as of March 31, 2026 was €12.0 million. Assuming the full use of the financing signed on April 21, 2026 (see post-period events below), up to a limit of €6 million, the Company is financed until the beginning of Q2 2027, it being specified that this cash runway does not consider any potential reven...